NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA) announced today that its PGxHealth Division has completed enrollment in a pivotal Phase III study of Vilazodone, in development for the treatment of depression. This randomized, double-blind, placebo-controlled trial was launched in the first quarter of 2006 and has now reached its target with dosing of 410 patients with major depressive disorder enrolled at ten investigative sites. This is one of two pivotal trials required for a new drug application, which the Company hopes to file with the United States Food & Drug Administration (FDA) in 2009. In conjunction with this study, Clinical Data is analyzing genetic biomarkers that may correlate with the prediction of response to Vilazodone. The Company anticipates announcing top-line efficacy and genetic biomarker results in the third calendar quarter of 2007.
